FDA Approves AUTUS: First Pediatric Heart Valve That Can Be Expanded as Children Grow

The U.S. Food and Drug Administration on October 1, 2026 approved the AUTUS Size-Adjustable Valve — the first heart valve in the United States designed to be expanded inside a child after implantation. The device aims to reduce the need for repeat open-heart surgeries by allowing clinicians to enlarge the valve noninvasively as a child grows.

How AUTUS Works

Implantation Size: The valve is implanted at roughly 13 millimeters in diameter to fit younger pediatric anatomies.
Expandable Range: Physicians can later expand the valve using a balloon catheter to about 22 millimeters, a size comparable to an adult pulmonary valve.
Leaflet Material: AUTUS is the first U.S.-approved heart valve to use synthetic polymeric leaflets instead of animal-derived tissue; these flexible flaps open and close to regulate blood flow.

Clinical Evidence

The FDA approved AUTUS based on a pivotal, multicenter study conducted at 12 U.S. sites that enrolled 62 pediatric patients. Key trial findings reported by the agency and the manufacturer include:

• All 62 patients had successful implantation procedures.
• At six months, 60 evaluated patients demonstrated acceptable blood flow and no more than mild pulmonary regurgitation (minor backward leakage).
• There were no deaths, strokes, or treatment-requiring blood clots reported during the follow-up period presented.
• Three patients experienced valve-frame fractures and two showed reduced motion of a single leaflet; none of these events produced symptoms according to the FDA.
• Two patients whose valves began to underperform as they grew underwent successful balloon expansion rather than repeat invasive surgery, though the FDA noted that expansion experience is still limited.

Safety, Limitations, And Next Steps

Edwards Lifesciences reported the trial met its primary safety and effectiveness endpoints. Regulators and clinicians describe early results as encouraging but emphasize key limitations: the study was small and follow-up short. One-year data so far support early leaflet durability, but longer follow-up is needed to determine how the synthetic leaflets and the expandable frame perform across a child’s full growth into adulthood.

The current evidence does not yet establish how many repeat surgeries AUTUS will ultimately prevent compared with conventional valves. Important unresolved questions include how often balloon expansions will be necessary, whether expansions are equally safe in different anatomies, and whether some patients will still require later interventions.

Regulatory Pathway And Indication

AUTUS was reviewed through the FDA’s premarket approval (PMA) pathway — the agency’s most rigorous review process for higher-risk medical devices — and previously held Breakthrough Device designation. The valve is approved for selected pediatric patients with congenital pulmonary valve disease and is not indicated for all children with congenital heart conditions.

What Families And Clinicians Should Know

The approval adds a new, regulated option for children who need pulmonary valve replacement and for families weighing long-term surgical plans. Edwards Lifesciences has planned a 10-year follow-up for study participants to provide longer-term evidence on durability and the device’s impact on future surgery rates — data families and clinicians will watch closely.

Bottom Line: AUTUS introduces an innovative, adjustable approach to pediatric pulmonary valve replacement, with promising early safety and function but important unanswered questions about long-term durability and real-world performance.